Recombinant proteins produced in insect cells.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Topics in Microbiology and Immunology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-3-540-92165-3_11PMID 19768408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

  2008cited by this paper
• Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

  2007cited by this paper
• Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

  2007cited by this paper
• Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus

  2007influential reference
• Commentary: From Scarcity to Abundance: Pandemic Vaccines and Other Agents for “Have Not” Countries

  2007cited by this paper
• Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.

  2007cited by this paper
• Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.

  2007cited by this paper
• Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.

  2006cited by this paper
• Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines.

  2006cited by this paper
• Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

  2006cited by this paper
• Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

  2006cited by this paper
• Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

  2006cited by this paper
• Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine

  2005cited by this paper
• Recommended composition of influenza virus vaccines for use in the 2005-2006 influenza season.

  2005cited by this paper
• Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

  2005influential reference
• Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.

  2005cited by this paper
• Baculovirus as versatile vectors for protein expression in insect and mammalian cells

  2005cited by this paper
• Protection of mice with recombinant influenza virus neuraminidase.

  2004cited by this paper
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

  2004cited by this paper
• A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

  2003cited by this paper
• Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

  2001cited by this paper
• Vaccines protect chickens against H5 highly pathogenic avian influenza in the face of genetic changes in field viruses over multiple years.

  2000cited by this paper
• Pathogenesis of and immunity to avian influenza A H5 viruses.

  2000cited by this paper
• Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998.

  1999cited by this paper
• Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.

  1999cited by this paper
• Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes.

  1999cited by this paper
• Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus.

  1998cited by this paper
• Options for the control of influenza III. Cairns, North Queensland, Australia (4-9 May 1996).

  1997cited by this paper
• Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults.

  1996cited by this paper
• Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein.

  1995cited by this paper
• Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.

  1995cited by this paper
• Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule.

  1989cited by this paper
• Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs.

  1989cited by this paper

• Current application status of baculovirus expression vector system

  2018cites this paper
• Ciências Biosynthesis and isolation of STEAP 1 protein from Escherichia coli cells lysates

  2016cites this paper
• Expression System Based on an MTIIa Promoter to Produce hPSA in Mammalian Cell Cultures

  2016cites this paper
• Insect cell surface expression of hemagglutinin (HA) of Egyptian H5N1 avian influenza virus under transcriptional control of whispovirus immediate early-1 promoter.

  2014cites this paper
• jmbReview Insect Cell Surface Expression of Hemagglutinin ( HA ) of Egyptian H 5 N 1 Avian Influenza Virus Under Transcriptional Control of Whispovirus Immediate Early-1 Promoter

  2014cites this paper
• Use of bacteriophage particles displaying influenza virus hemagglutinin for the detection of hemagglutination-inhibition antibodies.

  2014cites this paper
• Recombinant therapeutic protein vaccines.

  2013cites this paper
• Virus Glycoproteins Tagged with the Human Fc Domain as Second Generation Vaccine Candidates

  2012cites this paper
• Antigenic and immunogenic properties of recombinant hemagglutinin proteins from H1N1 A/Brisbane/59/07 and B/Florida/04/06 when produced in various protein expression systems.

  2012cites this paper
• Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.

  2011cites this paper
• Subcutaneous Immunization with Baculovirus Surface-Displayed Hemagglutinin of Pandemic H1N1 Influenza A Virus Induces Protective Immunity in Mice

  2011cites this paper
• Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.

  2011cites this paper
• Topical immunization strategies

  2010cites this paper
• Alternative influenza vaccines made by insect cells.

  2010cites this paper